heparitin-sulfate and Liver-Cirrhosis--Alcoholic

heparitin-sulfate has been researched along with Liver-Cirrhosis--Alcoholic* in 2 studies

Other Studies

2 other study(ies) available for heparitin-sulfate and Liver-Cirrhosis--Alcoholic

ArticleYear
[Case of cardial varices rupture due to danaparoid sodium with portal venous thrombosis].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:12

    A 54-year-old man had been admitted to Nara city hospital because of hematemesis and dyspnea caused by physical exertion, and was given a diagnosis of esophago-cardial varices and portal venous thrombosis. He was transferred to our hospital for further examinations and treatments. Ultrasonography (US) and computed tomography (CT) revealed the progression of portal venous thrombosis. Danaparoid sodium was administered to treat the portal vein thrombus. 5 days later, the patient was found to have hematemesis resulting from a cardial varices rupture. After endoscopic variceal ligation (EVL) and endoscopic injection sclerotherapy (EIS) was performed, danaparoid sodium was administered for 2 weeks. After the treatment, portal vein thrombus had almost disappeared. Due to an increased risk of bleeding, cases of esophago-cardial varices with portal venous thrombosis must be treated with care. This is the first report of upper gastrointestinal bleeding due to danaparoid sodium. Danaparoid sodium must be carefully administered when patients have portal venous thrombosis with delicate varices.

    Topics: Anticoagulants; Chondroitin Sulfates; Dermatan Sulfate; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hematemesis; Heparitin Sulfate; Humans; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Portal Vein; Sclerotherapy; Venous Thrombosis

2008
Presence and role of glycosaminoglycans in amyloidosis.
    Laboratory investigation; a journal of technical methods and pathology, 1987, Volume: 57, Issue:3

    Though the presence of glycosaminoglycans in amyloid deposits has been recognized for a long time their role in the pathogenesis of the disorder has remained elusive. As shown here, liver and spleen of human patients with secondary amyloidosis contain 5 to 10 times the amount of glycosaminoglycans as normal organs. Of the three major glycosaminoglycans measured, the heparan sulfate fraction showed the largest increase. In mice where amyloidosis was induced by the injection of casein and enhancing factor (accelerated model) 35SO4-labeled, or Alcian blue stained glycosaminoglycans appeared as early as and at the same location as proteins detected by Congo red staining which was about 2 days after initiation of the procedure. When glycosaminoglycan synthesis was followed in liver and spleen slices of control and experimental animals a significant increase in rate was found in the spleen of the experimental mice. Though there was an increase in heparan sulfate synthesis the major contribution to the overall increase was made by the chondroitin sulfates in the accelerated as well as in the standard induction model. In addition, unlike in the human disorder the chondroitin sulfates were the major glycosaminoglycans which had accumulated in the spleens of animals which had amyloidosis induced by the long term standard procedure (6 weeks) as measured by isolation and uronic acid analysis. The data presented here show that glycosaminoglycans appear to play an important and perhaps direct role in the process of amyloid deposition in the human disease as well as in the experimentally induced disorder in animals.

    Topics: Amyloidosis; Animals; Disease Models, Animal; Glycosaminoglycans; Heparitin Sulfate; Humans; In Vitro Techniques; Liver; Liver Cirrhosis, Alcoholic; Mice; Spleen

1987